69 articles
In Incyte Holdings Corporation v. Melody Healthcare, the Delhi High Court examined ruxolitinib patent infringement where the defendant had not launched a product but listed the API for…
The Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM) has released Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026…
Esteve Pharmaceuticals took its rejected co-crystal patent for tramadol and celecoxib to the Delhi High Court, arguing the combination showed real synergy. The court had to decide whether…
Novartis AG sought a quia timet patent injunction against Intas Pharmaceuticals Limited before the Delhi High Court, alleging that regulatory filings and an investigation report revealed imminent infringement…
When is a patent opposition board recommendation ripe for a writ petition, and when is it simply too soon? The Madras High Court tackled this question in a…
In the case of Boehringer Ingelheim Pharma GmbH & Co. KG v. Controller of Patents & Anr., the Delhi High Court addressed two important questions under the Patents…
A concise roundup of Intellepedia’s most impactful patent law articles of 2025, highlighting key judicial and Patent Office developments every IP practitioner should note.
The Delhi High Court refused Novo Nordisk interim relief against Dr Reddy’s, finding that the Semaglutide species patent faces serious validity challenges in light of the earlier genus…
The Delhi High Court reiterated that a properly drafted pharmaceutical composition claim cannot be dismissed as a “method of treatment” under Section 3(i), and has sent Medilabo’s neurodegenerative…
In a recent case the Madras High Court upheld Akebia Therapeutics’ appeal on its anaemia treatment patent, interpreting Section 59 to allow claim amendments from treatment methods to…